Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immune Thrombocytopenic Purpura (Sep 2019)

Posted by Matt Breese on Sep 20, 2019

Find me on:

According to our recent payer coverage analysis for immune thrombocytopenic purpura treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for immune thrombocytopenic purpura treatments shows that under the pharmacy benefit, about 63% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-ITP_3Q2019-finalData snapshot as of Q3 2019

Trends: In June 2019, the FDA gave an additional indication to Doptelet (avatrombopag) for the treatment of thrombocytopenia who have had an insufficient response to prior treatment.   

To read the full Reality Check on Immune Thrombocytopenic Purpura treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing